Time-dependent effect of tamoxifen therapy on endometrial pathology in asymptomatic postmenopausal breast cancer patients

International Journal of Gynecological Pathology

Volumn 15, Issue 2, 1996, Pages 152-157

  Cohen, Ilan ^a   Altaras, Marco M ^a   Shapira, Jeremiah ^a   Tepper, Ronnie ^a   Rosen, Doron J D ^a   Cordoba, Mario ^a   Zalel, Yaron ^a   Figer, Arie ^b,c   Yigael, Dror ^a   Beyth, Yoram ^a  

^a MEIR MEDICAL CENTER   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Endometrium; Long term treatment; Postmenopausal tamoxifen

Indexed keywords

TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; DOSE TIME EFFECT RELATION; ENDOMETRIUM; ENDOMETRIUM CANCER; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; POLYP; POSTMENOPAUSE; PRIORITY JOURNAL;

EID: 9244231748     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004347-199604000-00010     Document Type: Article

References (41)

1. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen- receptor-positive tumors. N Engl J Med 1989;320:479-84.
2. Bartlett K, Ermin O, Hutcheon A, et al. Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish trial. Lancet 1987;2:171-5.
3. Baum M, Brinkley DM, Dasset JA. Controlled trial of tamoxifen as a single adjuvant agent in management of early breast cancer. Br J Cancer 1988;57:608-11.
4. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 1992;339:1-15.
5. Early Breast Cancer Trialists' Collaborative Group, Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992;339:71-85.
6. Wolf DM, Jordan VC. Gynecologic complications associated with long-term adjuvant tamoxifen therapy for breast cancer. Gyncol Oncol 1992;45:118-28.
7. Wallgran A, Barae E, Carstensen J. Should adjuvant tamoxifen be given for several years in breast cancer? In: Jones SE, Salmon SE, eds. Adjuvant therapy of cancer: IV. New York: Grune & Stratton, 1984:331-7.
8. Neven P, De Muylder X, Van Belle Y, Vanderick G, De Muylder E. Tamoxifen and the uterus and endometrium. Lancet 1988;2:375.
9. Gal D, Kopel S, Bashevkim M, Lebowicz J, Lew R, Tancer ML. Oncogenic potential of tamoxifen on endometria of postmenopausal women with breast cancer: a preliminary report. Gynecol Oncol 1991;42:120-3.
10. De Muylder X, Neven P, De Somer M, Van Belle Y, Vanderick G, De Muylder E. Endometrial lesions in patients undergoing tamoxifen therapy. Int J Gynecol Obstet 1991; 36:127-30.
11. Cohen I, Rosen DJD, Shapira J, et al. Endometrial changes in postmenopausal women treated with tamoxifen for breast cancer. Br J Obstet Gynaecol 1993;100:567-70.
12. Lahti E, Blanco G, Kauppila A, Apaja-Sarkkinen M, Taskinen PJ, Laatikainen T. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 1993;81:660-4.
13. Cohen I, Rosen DJD, Shapira J, et al. Endometrial changes with tamoxifen: comparison between tamoxifen treated and non-treated asymptomatic, postmenopausal breast cancer patients. Gynecol Oncol 1994;52:185-90.
14. Cohen I, Tepper R, Rosen D, et al. Continuous tamoxifen treatment in asymptomatic, postmenopausal treated breast cancer patients does not cause aggravation of endometrial pathologies. Gynecol Oncol 1994;55:138-43.
15. Nuovo MA, Nuovo GJ, McCaffrey RM, Levine RU, Barren B, Winkler B, Endometrial polyps in postmenopausal patients receiving tamoxifen. Int J Gynecol Pathol 1989;8:125- 31.
16. Corley D, Rowe J, Curtis MT, Hogan WM, Noumoff JS, Livolsi VA. Postmenopausal bleeding from unusual endometrial polyps in women on chronic tamoxifen therapy. Obstet Gynecol 1992;79:111-6.
17. Cohen I, Shapira J, Altaras M, Cordoba M, Rosen DJD, Beyth Y. Endometrial decidual changes in a postmenopausal woman treated with tamoxifen and megestrol acetate. Br J Obstet Gynaecol 1992;99:773-4.
18. Cohen I, Figer A, Altaras MM, et al. Common endometrial decidual reaction in postmenopausal breast cancer patients treated with tamoxifen and progestogens. Int J Gynecol Pathol 1996;15:17-22.
19. Killackey MA, Hakes TB, Pierce VK. Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep 1985;69:237-8.
20. Hardell L. Tamoxifen as a risk factor for carcinoma of corpus uteri. Lancet 1988;3:563.
21. Fornander T, Cedermak B, Mattson A, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989;21:117-20.
22. Atlante G, Pozzi M, Vincenzoni C, Vocaturo, G. Four case reports presenting new acquisitions on the association of breast and endometrial cancer. Gynecol Oncol 1990;37:378- 80.
23. Malfetano JH. Tamoxifen-associated endometrial carcinoma in postmenopausal breast cancer patients. Gynecol Oncol 1990;39:82-4.
24. Mathew A, Chabon AB, Kabakow B, Drucker M, Hirschman RJ. Endometrial carcinoma in five patients with breast cancer on tamoxifen therapy. NY State J Med 1990; 90:207-8.
25. Andersson M, Storm HH, Mouridsen HT. Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst 1991;83: 1013-7.
26. Segna RA, Dottino PR, Deligolisch L, Cohen CJ. Tamoxifen and endometrial cancer. Mt Sinai J Med 1992;59:416-8.
27. Magriples U, Naftolin F, Schwartz PE, Cacangiu ML. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 1993;11:485-90.
28. Seoud M A-F, Johnson J, Weed JC. Gynecologic tumors in tamoxifen-treated women with breast cancer. Obstet Gynecol 1993;82:165-9.
29. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifentreated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) E-14. J Natl Cancer Inst 1994;86:527-37.
30. van Leeuwen FE, Benraadt J, Coebergh JWW, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994;343:448-52.
31. Altaras M, Aviram R, Cohen I, Cordoba M, Yarkoni S, Beyth Y. Role of prolonged stimulation of tamoxifen therapy in the etiology of endometrial sarcomas. Gynecol Oncol 1993;49:255-8.
32. Clarke MR. Uterine malignant mixed Mullerian tumor in a patient on long-term tamoxifen therapy for breast cancer: case report. Gynecol Oncol 1993;51:411-5.
33. Altaras M, Aviram R, Cohen I, Markov S, Beyth Y, Goldberg GL. Microhysteroscopy and endometrial biopsy results following failed diagnostic dilatation and curettage in women with postmenopausal bleeding. Int J Obstet Gynecol 1993; 42:255-60.
34. Mahboubi E, Eyler N, Wyler N. Epidemiology of cancer of the endometrium. Clin Obstet Gynecol 1982;25:5-17.
35. Rutquist LE, Cedarmark B, Fornander T. The relationship between hormone receptor content and the effect of adjuvant tamoxifen in operable breast cancer. J Clin Oncol 1989; 7:1474-84.
36. Gottardis MM, Robinson SP, Jordan VC. Estradiol stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen. J Steroid Biochem 1988;30:311.
37. Jordan VC, Lababidi MK, Mirecki DM. Antiestrogenic and anti-tumour properties of prolonged tamoxifen therapy in C3H/OUJ mice. Eur J Cancer 1990;26:718-21.
38. Jordan VC, Lababidi MK, Langan-Fahey S. Suppression of mouse mammary tumorigenesis by long-term tamoxifen therapy. J Natl Cancer Inst 1991;83:492-6.
39. Jordan VC. Laboratory evidence to support the use of long-term adjuvant tamoxifen therapy for breast cancer. Horm Res 1984;32(suppl):261-5.
40. Gusberg SB. Tamoxifen for breast cancer: associated endometrial cancer [Editorial]. Cancer 1990;65:1463-4.
41. Archer DF, McIntyre-Seltman K, Wilborn WW Jr, et al. Endometrial morphology in asymptomatic postmenopausal women. Am J Obstet Gynecol 1991;165:317-22.